Last reviewed · How we verify
NCT04444193: Dulect2020-2
Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma
NA trial testing Durvalumab in Endometrial Cancer in 20 participants. Status unknown.
31 May 2021
Quick facts
| Lead sponsor | Shanghai First Maternity and Infant Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 31 August 2020 |
| Primary completion | 31 May 2021 |
| Estimated completion | 31 May 2021 |
Drugs / interventions tested
- Durvalumab — full drug profile →
- Lenvatinib Oral Product — full drug profile →
Conditions studied
- Endometrial Cancer — all drugs for Endometrial Cancer →
Sponsor
Shanghai First Maternity and Infant Hospital
Who can join
Adults 18 to 80, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the safety and efficacy of durvalumab in combination with lenvatinib in participants with advanced and recurrent endometrial carcinoma.The primary hypothesis of this study are that patients with advanced and recurrent endometrial carcinoma could benefit from durvalumab plus lenvatinib with respect to: 1)Progression Free Survival (PFS) ; 2) Objective Response Rate (ORR); and Overall survival (OS). The investigators design a clinical study to explore whether the combination above as a treatment in patients with advanced and recurrent endometrial carcinoma could prolong PFS and to analyze potential immune biomarker of therapeutic response.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.
Petrazzuolo A, Maiuri MC, Zitvogel L, Kroemer G, et al · · 2022 · cited 23× · PMID 35655707 · DOI 10.1080/2162402x.2022.2077898 -
How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.
Maiorano BA, Maiorano MFP, Cormio G, Maglione A, et al · · 2022 · cited 19× · PMID 35494078 · DOI 10.3389/fonc.2022.844801 -
Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis.
Johnson RL, Ganesan S, Thangavelu A, Theophilou G, et al · · 2023 · cited 7× · PMID 37760602 · DOI 10.3390/cancers15184632
Verify or expand the search:
- PubMed search for NCT04444193
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Durvalumab
Trials testing the same drug.
- NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
- NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
- NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
- NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting
Other recruiting trials for Endometrial Cancer
Currently open trials in the same condition.
- NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
- NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
- NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
- NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
- NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting
Other Shanghai First Maternity and Infant Hospital trials
Trials by the same sponsor.
- NCT07426146 — Feasibility Effects of a Low-GI, High-fibre Diet in PCOS: a Prospective Cohort Study in Remote Yunnan · recruiting
- NCT06093984 — Cumulative Live Birth Rates in Dual Ovarian Stimulation Versus Two Antagonist Stimulations in Poor Ovarian Responders · NA · not yet recruiting
- NCT06049186 — CRD vs. Met in Patients With Obese PCOS Infertility · NA · unknown
- NCT06096805 — Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR) · recruiting
- NCT06104748 — A Cohort of Maternal Vascular Malperfusion-related FGR (CoMVMFGR) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04444193 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai First Maternity and Infant Hospital
- Last refreshed: 23 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04444193.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing